Joenja — Medical Mutual
Activated Phosphoinositide 3-kinase Delta Syndrome (APDS), continuation of therapy
Reauthorization criteria
- Patient has been established on therapy for at least 6 months
- Patient is ≥ 12 years of age
- Patient weighs ≥ 45 kg
- Patient has a genetic phosphoinositide 3-kinase delta (PI3Kδ) pathogenic variant in the PIK3CD and/or PIK3R1 genes
- Patient has had a positive clinical response in the signs and manifestations of APDS
Approval duration
1 year